Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFIC

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

116

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

February 15, 2024

Study Completion Date

October 10, 2025

Conditions
Progressive Familial Intrahepatic Cholestasis
Interventions
DRUG

A4250 (odevixibat)

A4250 is a small molecule and selective inhibitor of IBAT

Trial Locations (41)

10029

Icahn School of Medicine at Mount Sinai, New York

10032

Columbia University Medical Center - Presbyterian Hospital Building, New York

15224

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

21287

Johns Hopkins School of Medicine, Baltimore

30329

Emory University School of Medicine, Atlanta

46202

Riley Hospital for Children - Riley Children's Specialists, Indianapolis

63110

Washington University School of Medicine, St Louis

77030

Baylor College of Medicine - Texas Children's Liver Center, Houston

80045

Children's Hospital Colorado, Denver

90027

Children's Hospital Los Angeles, Los Angeles

Unknown

The Royal Children's Hospital, Melbourne

Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert

The Hospital for Sick Children, Toronto

University and Pediatric Hospital of Lyon, Bron

Universite Paris SUD - Hpitaux Universitaires Paris-Sud - Hopital Bicetre, Le Kremlin-Bicêtre

Hospital De La Timone, Marseille

Hospital Necker-Enfants Maladies, Paris

Medizinische Hochschule Hannover, Hanover

Kinderklinik Tubingen, Universitatsklinikum Tubingen, Tübingen

Univesitatsklinikum Tubingen Klinik fur Kinder und Jugendmedizin, Tübingen

Shaare-Zedek Mc, Jerusalem

Schneider Children's Medical Center Of Israel, Petah Tikva

Azienda Ospedaliera Papa Giovanni XXIII, Bergamo

University Hospital Of Padova, Padua

Ospedale Regina Margherita, Torino

University Medical Center Groningen, Groningen

Universitair Medisch Centrum (UMC) Utrecht, Utrecht

Instytut Pomnik - Centrum Zarowia Dziecka, Warsaw

King Faisal Specialist Hospital & Research Centre, Riyadh

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Universitario La Paz, Madrid

Astrid Lindgren Children's Hospital, Karolinska University Hospital, Solna

Gazi University, Ankara

Hacettepe University Faculty of Medicine, Ankara

Akdeniz University, Antalya

Istanbul University Medical Faculty, Istanbul

Inonu University Medical Faculty, Malatya

Birmingham Women's and Children's NHS Foundation Trust, Birmingham

Leeds General Infirmary, Leeds

Institute of Liver Studies - Kings College Hospital, London

All Listed Sponsors
lead

Albireo, an Ipsen Company

INDUSTRY